Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for

Core Viewpoint - The market anticipates a year-over-year decline in earnings for Amicus Therapeutics despite higher revenues, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - Amicus Therapeutics is expected to report earnings of $0.02 per share, reflecting a year-over-year decrease of 66.7%, while revenues are projected to be $147.5 million, an increase of 16.4% from the previous year [3]. - The earnings report is scheduled for July 31, and better-than-expected results could lead to a stock price increase, whereas disappointing results may cause a decline [2]. Estimate Revisions - The consensus EPS estimate has been revised 10% higher in the last 30 days, indicating a collective reassessment by analysts [4]. - The Most Accurate Estimate for Amicus Therapeutics is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +191.67%, although the stock has a Zacks Rank of 4, complicating predictions of an earnings beat [12]. Earnings Surprise History - In the last reported quarter, Amicus Therapeutics was expected to post earnings of $0.08 per share but only achieved $0.03, resulting in a surprise of -62.50% [13]. - Over the past four quarters, the company has surpassed consensus EPS estimates twice [14]. Industry Comparison - NeoGenomics, another company in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings of $0.03 per share, unchanged from the previous year, with revenues projected at $182.93 million, up 11.2% [18]. - NeoGenomics has an Earnings ESP of -22.22% and a Zacks Rank of 2, making it difficult to predict an earnings beat despite a history of surpassing estimates [19][20].